To the full analysis
Max Healthcare Institute stock: growth
MAXHEALTH.NSMax Healthcare Institute reported $890M in revenue for fiscal 2026, up 19.1% on the prior year, up 27.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
19.9%
per year from 2014 to 2026, per share 11.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
17.4%
per year from 2014 to 2026, per share 9.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2014 | |
|---|---|---|---|
| Revenue | 27.3% | 19.3% | 19.9% |
| Revenue per share | 24.3% | 12.6% | 11.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | 17.4% |
| Free cash flow per share | no data | no data | 9.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $100.39M | −$6.87M | $2.31M |
| 2015 | $83.92M | −$4.05M | −$1.66M |
| 2016 | $152.45M | −$2.4M | −$93.86M |
| 2017 | $170.96M | $1.68M | $4.36M |
| 2018 | $183.91M | −$2.21M | $1.77M |
| 2019 | $180.04M | −$319.93K | −$2.85M |
| 2020 | $112.56M | $6.27M | $17.12M |
| 2021 | $266.57M | −$14.62M | −$59.52K |
| 2022 | $418.41M | $64.31M | $19.9M |
| 2023 | $484.95M | $117.29M | $92.85M |
| 2024 | $574.6M | $112.41M | $35.68M |
| 2025 | $747.04M | $114.35M | $52.48M |
| 2026 | $890M | $153.31M | $15.81M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.